In U-2932 cells, 0.5 mM altretamine increased lipid ROS. A separate 1 mM treatment left reduced-glutathione levels similar to vehicle control, consistent with an effect downstream of GSH depletion. These readouts alone do not demonstrate ferroptotic cell death. [1]
In ovarian carcinoma E cells, hexamethylmelamine activity depended on exposure time: 0.1–10 µg/ml produced little change in thymidine uptake after 48 h, whereas 120 h exposure reduced uptake. Low-dose effects largely reversed after drug removal. The endpoint measures DNA synthesis, and the highest nominal concentration (100 µg/ml) was incompletely soluble. [2]
GPX4 lipid-hydroperoxide reduction in treated-cell lysates
Biochemical assay · Lysates from human U-2932 diffuse large B-cell lymphoma cells [1]
Lysates from altretamine-treated cells retained a PC-OOH signal, whereas untreated lysates reduced the substrate. No-lysate material supplied a substrate control. This supports impaired GPX4-associated lipid repair in this lysate assay; it does not establish direct binding or a purified-enzyme IC50.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.5 mM altretamine (cell treatment, Figure 5B)
- Exposure duration
- Cell-treatment duration not specified in the acquired Figure 5B/caption or relevant main methods; lysate reaction: 30 min at 37°C.
- Method
- LC-MS quantification of PC-OOH after incubation with 200 µg cellular protein and reduced glutathione.
- Reported limits
- Treatment duration and panel-specific replicate count not specified in the acquired main text/figure. SI was not retrieved. Chemical supplier/purity not established in acquired scope.
Methods and source locations
Compound reported in the paper: Altretamine; Compound label in the paper: ALT
Evidence concerns the named compound in the reported experimental system; supplier, purity and Adooq lot equivalence are not established.
Figure 5B and caption; altretamine Results; GPX4 enzymatic activity assay
Residual phosphatidylcholine hydroperoxide after lysate incubation: LC-MS, [PC-OOH + H+] m/z = 790.5; no-lysate and untreated-lysate controls. — Figure 5B image/caption and Results; GPX4 assay methods
Lipid oxidation and glutathione response in U-2932 cells
Cell-based study · Human U-2932 diffuse large B-cell lymphoma cells [1]
Altretamine increased the lipid-ROS-positive population at 0.5 mM. At the separate 1 mM condition, reduced-glutathione levels were similar to DMSO control; sulfasalazine depleted GSH and increased lipid ROS. The linked pathway readouts were obtained at different concentrations and do not establish ferroptotic death by themselves.
Literature-Reported Treatment Conditions
- Treatment concentration
- Altretamine: 0.5 mM for lipid ROS; 1 mM for GSH. Sulfasalazine comparator: 1 mM.
- Exposure duration
- Panel-specific drug exposure duration not specified in acquired main text/figure.
- Method
- C11-BODIPY flow cytometry for lipid ROS; Ellman reagent for GSH.
- Vehicle
- DMSO control; concentration not specified for these panels.
- Reported limits
- SI not acquired; panel-specific exposure times and GSH replicate/error-bar definition not established. Do not substitute profiling or viability-assay conditions.
Methods and source locations
Compound reported in the paper: Altretamine; Compound label in the paper: ALT
Evidence concerns the named compound in the reported experimental system; supplier, purity and Adooq lot equivalence are not established.
Figure 5A,C and caption; altretamine Results; cell culture and lipid ROS methods
Fraction within the displayed lipid-ROS gate: C11-BODIPY flow cytometry; biological triplicates, representative result displayed. — Figure 5C image and caption; Analysis of lipid ROS generation
Reduced glutathione normalized to protein: Ellman reagent; exact bar heights and error semantics not extracted. — Figure 5A image/caption; altretamine Results
Exposure-time dependence and recovery in ovarian carcinoma E cells
Cell-based study · E cell line derived from human ovarian carcinoma [2]
HMM had little effect on thymidine uptake at 0.1–10 µg/ml after 48 h. After 120 h, uptake fell at 0.1 µg/ml and at 100 µg/ml. Recovery after drug removal was concentration dependent. These DNA-synthesis readouts are not an IC50 or a direct cell-death count. No PMM or HMPMM was detected in medium in a separate 24 h metabolism check, but the authors explicitly did not exclude low-level activation below detection.
Literature-Reported Treatment Conditions
- Treatment concentration
- HMM 0.1, 1, 10 or 100 µg/ml; 100 µg/ml incompletely soluble.
- Exposure duration
- Time-course experiments: 1–120 h exposure; key tabulated endpoints 48 h and 120 h, with 72 h drug-free recovery after 120 h.
- Method
- Growth-medium exposure; drug-containing medium renewed every 24 h. [3H]thymidine added for the last 6 h of treatment or recovery.
- Vehicle
- Growth medium (MEM with 10% fetal calf serum and supplements).
- Reported limits
- Control is untreated growth-medium cells. n is reported as 10–20 samples per time and concentration, not a fixed biological-replicate count. Dissolved exposure at nominal 100 µg/ml is unknown.
Methods and source locations
Compound reported in the paper: Altretamine; Compound label in the paper: HMM
Evidence concerns the named compound in the reported experimental system; supplier, purity and Adooq lot equivalence are not established.
Pages 631–634: Methods, Tables I–II, Figure 1/caption, Figure 2/caption, Results/Discussion
[3H]thymidine uptake after 48 h, percentage of control: [3H]thymidine uptake; untreated controls. — Page 631, Table I and Methods
[3H]thymidine uptake after 120 h and after subsequent 72 h drug-free recovery: Dunnett test: P < 0.01 versus controls for 62 ± 5.7, 51 ± 2.3 and 38 ± 2.9; not marked significant for 92 ± 8.9. 10–20 samples per time/concentration. — Page 631, Table II and Methods
Metabolite detection in medium after HMM exposure: Gas chromatography of medium extracts; spiked HMM/PMM/TMM reference chromatogram. — Page 633, Figure 2/caption and Results; page 634 Discussion caveat